# OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

> **NCT02445326** · PHASE3 · COMPLETED · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 73 (actual)

## Conditions studied

- Chronic Allergic Conjunctivitis

## Interventions

- **DRUG:** Dexamethasone
- **OTHER:** Placebo Vehicle

## Key facts

- **NCT ID:** NCT02445326
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445326, "OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02445326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*